Skip to main content
. Author manuscript; available in PMC: 2022 Aug 9.
Published in final edited form as: Oncogene. 2021 Nov 20;41(5):671–682. doi: 10.1038/s41388-021-02118-4

Figure 1. Amplification of CSN5 is correlated with poor clinical outcomes in prostate cancer.

Figure 1.

A, Genomic alterations of CSN5 cross 24 cancer types; 176 clinical cohort studies which includes 46716 patient samples from cBioPortal for Cancer Genomics were used for this analysis. The alteration frequency threshold is above 0.5%. B, Genomic alterations of CSN5 in prostate cancer cohorts. Seven prostate cancer cohorts from cBioPortal were used for the analysis. Alteration frequency of CSN5 is listed in the left panel, and the tumor type distribution of each cohort is listed in the right panel. C-D, The correlation of CSN5 alteration with fraction genomic altered (FGA) and Gleason score in the MSKCC/DFCI cohort (C) and MSKCC cohort (D). E, The correlation between CSN5 alteration and tumor progression in MSKCC and Grasso cohorts. CSN5 copy number was analyzed in primary (Pri), and metastasis (Met) tissue samples. F and G, the correlation between CSN5 alteration and clinical outcomes in TCGA and SU2C cohorts. P-value is between amplification and diploid of CSN5.